Our goal is to become one of the leading specialty pharmaceutical companies developing, registering and supporting valuable medicines that significantly improve patients' lives.
Since 2010, Mallinckrodt has received U.S. Food and Drug Administration approval for 14 drugs across our portfolio. Today, we have more than two dozen products in development. We are also executing key company-sponsored studies directed at defining the efficacy, safety, and health economic benefits of our key products.
Mallinckrodt's exceptional strength in drug reformulation has bolstered our position as an industry leader in the development and manufacturing of specialty generic drugs. This continues to be a significant R&D focus.